|
|
Vaccine Detail
|
Recombinant Fowlpox GM-CSF Vaccine Adjuvant |
| Vaccine Information |
- Vaccine Name: Recombinant Fowlpox GM-CSF Vaccine Adjuvant
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007002
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- GM-CSF (human)
gene engineering:
- Type: Recombinant vector construction
- Description: (Kass et al., 2001)
- Detailed Gene Information: Click Here.
- Preparation: Avipox(F)-GM-CSF was constructed via homologous recombination in vivo between the parental fowlpox DNA and a plasmid vector that contains the murine GM-CSF gene (Kass et al., 2001).
- Description: This is for Bladder Cancer (NCT00072137). A cancer vaccine adjuvant consisting of a recombinant fowlpox virus encoding human granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF binds to specific cell surface receptors on various immuno-hematopoietic cell types, enhancing their proliferation and differentiation and stimulating macrophage and dendritic cell functions in antigen presentation and antitumor cell-mediated immunity. Administration of recombinant fowlpox GM-CSF vaccine adjuvant may induce an immune response against tumor cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells (Reali et al., 2005; NCIT_C2686).
|
| Host Response |
|
|
| References |
Kass et al., 2001: Kass E, Panicali DL, Mazzara G, Schlom J, Greiner JW. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer research. 2001; 61(1); 206-214. [PubMed: 11196163].
NCIT_C2686: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2686]
NCT00072137: [https://clinicaltrials.gov/ct2/show/NCT00072137?term=Recombinant+Fowlpox+GM-CSF+Vaccine+Adjuvant&rank=1]
Reali et al., 2005: Reali E, Canter D, Zeytin H, Schlom J, Greiner JW. Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms. Vaccine. 2005; 23(22); 2909-2921. [PubMed: 15780740].
|
|
